Welcome to our dedicated page for Cyclerion Therapeutics news (Ticker: CYCN), a resource for investors and traders seeking the latest updates and insights on Cyclerion Therapeutics stock.
Cyclerion Therapeutics, Inc. (Nasdaq: CYCN) is a clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing treatments for serious and orphan diseases. Established in 2018 and headquartered in Cambridge, Massachusetts, Cyclerion harnesses the potential of soluble guanylate cyclase (sGC) pharmacology to create groundbreaking therapies for conditions with significant unmet medical needs.
The company's portfolio includes several promising product candidates:
- Olinciguat: An orally administered vascular sGC stimulator currently in Phase II studies aimed at treating sickle cell disease (SCD).
- Praliciguat: An orally administered systemic sGC stimulator in Phase II trials targeting diabetic nephropathy and heart failure with preserved ejection fraction.
- IW-6463: An orally administered, CNS-penetrant sGC stimulator in Phase I trials for neurodegenerative diseases.
In addition to these advanced candidates, Cyclerion is also working on discovering liver-targeted and lung-targeted sGC stimulators.
One of the latest developments for Cyclerion is its strategic partnership with Tisento Therapeutics, Inc. In July 2023, Cyclerion announced the closing of an asset purchase agreement with Tisento, which includes an $81 million Series A financing to support the development of Phase 2 soluble guanylate cyclase (sGC) stimulator zagociguat and other assets. Cyclerion received 10 percent equity ownership in Tisento, providing its shareholders with future value creation opportunities.
Cyclerion’s collaboration with Tisento marks a significant advancement, particularly for the brain-penetrant sGC stimulators zagociguat and CY3018. Phase 2a data from Cyclerion's studies demonstrated that zagociguat could significantly improve disease-associated biomarkers in patients with MELAS (Mitochondrial Encephalomyopathy, Lactic Acidosis, and Stroke-like episodes), offering hope for better treatment options where none previously existed.
With a focus on delivering new therapeutic solutions, Cyclerion continues to explore collaborations, licenses, and other strategic options to enhance shareholder value while advancing its portfolio of innovative treatments.
Cyclerion Therapeutics (CYCN) announced key updates on monetizing its sGC stimulator portfolio. The company renegotiated its praliciguat license agreement with Akebia, securing $1.75 million in upfront and near-term payments, plus potential future milestone payments up to $560 million and tiered sales royalties from mid-single-digits to 20%.
Additionally, CYCN entered an exclusive license option agreement for olinciguat with a CVCO Therapeutics-controlled entity. This follows the May 2023 sale of CNS assets zagociguat and CY3018 to Tisento Therapeutics for $8 million and 10% equity stake.
These agreements represent the final steps in monetizing Cyclerion's historical portfolio, enabling the company to focus on acquiring new CNS assets without near-term dilution.
Cyclerion Therapeutics (Nasdaq: CYCN) has promoted Regina Graul, Ph.D., to Chief Executive Officer, President, and Board member. Since joining in December 2023, Dr. Graul has focused on reducing operating costs and leading a search and evaluation team to assess multiple business development prospects. The company's Board of Directors expressed confidence in her ability to drive growth and success.
Dr. Graul emphasized her commitment to continuing Cyclerion's evolution, highlighting the formation of a top-notch diligence team currently evaluating promising assets. She acknowledged the challenges ahead but expressed confidence in the company's potential to unlock value for patients and shareholders.
Cyclerion Therapeutics (Nasdaq: CYCN) announced that its Independent Board is pursuing a non-binding proposal from a group including its CEO to acquire its zagociguat and CY3018 assets. The Board has entered into exclusive negotiations for this transaction. Additionally, CEO Peter Hecht is set to invest $5 million in equity for Cyclerion, contingent on successful negotiation of documentation. This investment aims to support ongoing operations. All actions remain subject to Board and shareholder approvals, and there is no guarantee of successful completion.
FAQ
What is the current stock price of Cyclerion Therapeutics (CYCN)?
What is the market cap of Cyclerion Therapeutics (CYCN)?
What does Cyclerion Therapeutics, Inc. specialize in?
What are some of the key products in Cyclerion’s pipeline?
What recent partnership did Cyclerion enter?
What is zagociguat?
Where is Cyclerion Therapeutics headquartered?
What are the financial benefits of Cyclerion’s deal with Tisento?
Who are the major investors in Tisento’s Series A financing?
What is the focus of Cyclerion’s research and development?
What distinguishes Cyclerion’s approach to drug development?
How can investors and media contact Cyclerion?
